ATE312934T1 - Rekombinant bakterielle system mit umweltbeschränkte lebensfähigkeit - Google Patents
Rekombinant bakterielle system mit umweltbeschränkte lebensfähigkeitInfo
- Publication number
- ATE312934T1 ATE312934T1 AT96919292T AT96919292T ATE312934T1 AT E312934 T1 ATE312934 T1 AT E312934T1 AT 96919292 T AT96919292 T AT 96919292T AT 96919292 T AT96919292 T AT 96919292T AT E312934 T1 ATE312934 T1 AT E312934T1
- Authority
- AT
- Austria
- Prior art keywords
- genes
- permissive
- environment
- environmentally
- microorganisms
- Prior art date
Links
- 230000035899 viability Effects 0.000 title abstract 6
- 230000001580 bacterial effect Effects 0.000 title abstract 2
- 230000007613 environmental effect Effects 0.000 title 1
- 244000005700 microbiome Species 0.000 abstract 5
- 108700005090 Lethal Genes Proteins 0.000 abstract 4
- 229960005486 vaccine Drugs 0.000 abstract 4
- 239000000427 antigen Substances 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 230000001105 regulatory effect Effects 0.000 abstract 3
- 230000028993 immune response Effects 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 108700039887 Essential Genes Proteins 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 241000607142 Salmonella Species 0.000 abstract 1
- 230000002759 chromosomal effect Effects 0.000 abstract 1
- 230000004720 fertilization Effects 0.000 abstract 1
- 230000003071 parasitic effect Effects 0.000 abstract 1
- 244000052769 pathogen Species 0.000 abstract 1
- 230000004083 survival effect Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
Landscapes
- Genetics & Genomics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47378995A | 1995-06-07 | 1995-06-07 | |
| PCT/US1996/009774 WO1996040947A1 (en) | 1995-06-07 | 1996-06-07 | Recombinant bacterial system with environmentally limited viability |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE312934T1 true ATE312934T1 (de) | 2005-12-15 |
Family
ID=23880978
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT96919292T ATE312934T1 (de) | 1995-06-07 | 1996-06-07 | Rekombinant bakterielle system mit umweltbeschränkte lebensfähigkeit |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US6610529B1 (de) |
| EP (1) | EP0832255B1 (de) |
| JP (1) | JPH11507532A (de) |
| AT (1) | ATE312934T1 (de) |
| AU (1) | AU711618B2 (de) |
| CA (1) | CA2222761A1 (de) |
| DE (1) | DE69635579D1 (de) |
| WO (1) | WO1996040947A1 (de) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996040947A1 (en) * | 1995-06-07 | 1996-12-19 | Washington University | Recombinant bacterial system with environmentally limited viability |
| CN1131889C (zh) | 1996-03-13 | 2003-12-24 | 宝酒造株式会社 | 质粒 |
| US6942861B2 (en) * | 1996-04-19 | 2005-09-13 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Histidine-tagged intimin and methods of using intimin to stimulate an immune response and as an antigen carrier with targeting capability |
| US6537558B2 (en) | 1997-03-31 | 2003-03-25 | Megan Health, Inc. | Methods of producing and using virulence attenuated poxR mutant bacteria |
| US6099848A (en) * | 1997-11-18 | 2000-08-08 | The Trustees Of The University Of Pennsylvania | Immunogenic compositions comprising DAL/DAT double-mutant, auxotrophic, attenuated strains of Listeria and their methods of use |
| ES2343304T3 (es) * | 1999-06-25 | 2010-07-28 | Wyeth Holdings Corporation | Produccion de la forma lipidada de las lipoproteinas asociadas a peptidoglicano de bacterias gram-negativas. |
| US9012141B2 (en) | 2000-03-27 | 2015-04-21 | Advaxis, Inc. | Compositions and methods comprising KLK3 of FOLH1 antigen |
| US6780405B1 (en) * | 2000-04-28 | 2004-08-24 | Avant Immunotherapeutics, Inc. | Regulated antigen delivery system (RADS) |
| GB0012233D0 (en) * | 2000-05-19 | 2000-07-12 | Devgen Nv | Vector constructs |
| US7780961B2 (en) | 2001-05-03 | 2010-08-24 | Actogenix N.V. | Self-containing Lactococcus strain |
| WO2004001020A2 (en) | 2002-06-19 | 2003-12-31 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Methods and means to promote gut absorption |
| AU2006319216B2 (en) | 2005-11-29 | 2012-09-13 | Intrexon Actobiotics Nv | Induction of mucosal tolerance to antigens |
| US20110183319A1 (en) * | 2010-01-22 | 2011-07-28 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Compositions and methods for therapeutic delivery with microorganisms |
| US8682619B2 (en) * | 2005-12-14 | 2014-03-25 | The Invention Science Fund I, Llc | Device including altered microorganisms, and methods and systems of use |
| US9005944B2 (en) | 2005-12-14 | 2015-04-14 | The Invention Science Fund I, Llc | Bone cell delivery device |
| US8900865B2 (en) | 2005-12-14 | 2014-12-02 | The Invention Science Fund I, Llc | Blood brain barrier device |
| US9061075B2 (en) | 2005-12-14 | 2015-06-23 | The Invention Science Fund I, Llc | Bone delivery device |
| US20110172826A1 (en) * | 2005-12-14 | 2011-07-14 | Amodei Dario G | Device including altered microorganisms, and methods and systems of use |
| US8354258B2 (en) | 2005-12-14 | 2013-01-15 | The Invention Science Fund I, Llc | Diatom device |
| US8734823B2 (en) * | 2005-12-14 | 2014-05-27 | The Invention Science Fund I, Llc | Device including altered microorganisms, and methods and systems of use |
| US8278094B2 (en) | 2005-12-14 | 2012-10-02 | The Invention Science Fund I, Llc | Bone semi-permeable device |
| US8198080B2 (en) | 2005-12-14 | 2012-06-12 | The Invention Science Fund I, Llc | Bone delivery device |
| US20080124355A1 (en) * | 2006-09-22 | 2008-05-29 | David Gordon Bermudes | Live bacterial vaccines for viral infection prophylaxis or treatment |
| EP3351268B1 (de) | 2007-01-25 | 2020-08-05 | Intrexon Actobiotics NV | Behandlung von immunerkrankungen durch mukosale abgabe von antigenen |
| CN101730737B (zh) * | 2007-04-24 | 2016-06-01 | 赛尔戴克斯治疗公司 | 超表达重组霍乱毒素b亚单位的霍乱弧菌显示双重免疫原性 |
| EP2150616A4 (de) | 2007-05-10 | 2011-07-27 | Univ Arizona | Geregelte antigensynthese und/oder geregelte attenuation zur verbesserung der impfstoff immunogenität und/oder -sicherheit |
| US20100317084A1 (en) * | 2007-05-10 | 2010-12-16 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Recombinant bacteria comprising vectors for expression of nucleic acid sequences encoding antigens |
| US9040059B2 (en) | 2007-10-05 | 2015-05-26 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Recombinant bacterium capable of eliciting a protective immune response against C. perfringens |
| US9650639B2 (en) | 2008-05-19 | 2017-05-16 | Advaxis, Inc. | Dual delivery system for heterologous antigens |
| US9017660B2 (en) | 2009-11-11 | 2015-04-28 | Advaxis, Inc. | Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors |
| EP2853269B1 (de) | 2008-05-19 | 2019-05-01 | Advaxis, Inc. | Doppeltes Freisetzungssystem für heterologe Antigene umfassend einen rekombinanten Listeria - Stamm, attenuiert durch Mutation von dal / dat und Deletion von ActA, umfassend ein Nukleinsäuremolekül, das ein Listeriolysin O - Prostata - spezifisches Antigen - Fusionsprotein codiert |
| NO2337846T3 (de) * | 2008-09-26 | 2018-06-16 | ||
| WO2010045620A1 (en) | 2008-10-17 | 2010-04-22 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Recombinant bacterium capable of eliciting an immune response against streptococcus pneumoniae |
| US9163219B2 (en) | 2009-04-14 | 2015-10-20 | Arizona Board Of Regents On Behalf Of Arizona State University | Single expression vector for generation of a virus with a segmented genome |
| US8551749B2 (en) | 2009-04-23 | 2013-10-08 | The Invention Science Fund I, Llc | Device including bone cage and method for treatment of disease in a subject |
| WO2010135563A1 (en) | 2009-05-22 | 2010-11-25 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Recombinant bacterium and methods of antigen and nucleic acid delivery |
| US9045742B2 (en) | 2009-05-29 | 2015-06-02 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Recombinant Edwardsiella bacterium |
| US10016617B2 (en) | 2009-11-11 | 2018-07-10 | The Trustees Of The University Of Pennsylvania | Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers |
| US9062297B2 (en) | 2010-01-13 | 2015-06-23 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Yersinia pestis vaccine |
| WO2011091291A1 (en) | 2010-01-22 | 2011-07-28 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | BACTERIUM COMPRISING A REGULATED rfaH NUCLEIC ACID |
| WO2011150421A2 (en) | 2010-05-28 | 2011-12-01 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Recombinant bacterium to decrease tumor growth |
| US9255283B2 (en) | 2010-07-02 | 2016-02-09 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Compositions and methods for bacterial lysis and neutral lipid production |
| CN103282048B (zh) | 2010-10-01 | 2017-05-17 | 宾夕法尼亚大学理事会 | 李斯特菌疫苗载体用于在寄生虫感染的个体中扭转免疫无应答的用途 |
| WO2012054693A1 (en) * | 2010-10-22 | 2012-04-26 | Trudeau Institute | Uses of yersinia yope peptide, gene, and subparts thereof as a plague vaccine component and assays for yersinia pestis-specific t cells |
| WO2012087483A1 (en) * | 2010-11-24 | 2012-06-28 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Recombinant bacterium comprising a toxin/antitoxin system |
| US20120107888A1 (en) * | 2011-02-17 | 2012-05-03 | Qteros, Inc. | Modulation of fermentation products through vitamin supplementation |
| CA2829960A1 (en) | 2011-03-11 | 2012-09-20 | John Rothman | Listeria-based adjuvants |
| KR20140134695A (ko) | 2012-03-12 | 2014-11-24 | 어드박시스, 인크. | 리스테리아 백신 치료 후 억제 세포 기능 저해 |
| US9303264B2 (en) | 2012-05-18 | 2016-04-05 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Photosynthetic microorganisms expressing thermostable lipase |
| EP2880166A4 (de) * | 2012-08-02 | 2016-04-20 | Univ Central Florida Res Found | Zusammensetzungen und verfahren für genetische konstrukte |
| WO2014145346A2 (en) * | 2013-03-15 | 2014-09-18 | Bacterial Robotics, Llc | Compositions, systems and methods for protecting genetically modified organisms from unauthorized use or release into the environment |
| US9580718B2 (en) | 2013-06-17 | 2017-02-28 | Arizona Board Of Regents On Behalf Of Arizona State University | Attenuated live bacteria with increased acid resistance and methods of use thereof |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| EP3445857B1 (de) | 2016-04-20 | 2023-07-05 | The Board of Trustees of the Leland Stanford Junior University | Zusammensetzungen und verfahren zur nukleinsäureexpression und proteinsekretion bei bakteroiden |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| AU2017376780B2 (en) | 2016-12-15 | 2024-12-12 | Novome Biotechnologies, Inc. | Compositions and methods for modulating growth of a genetically modified gut bacterial cell |
| CA3084954A1 (en) | 2017-12-05 | 2019-06-13 | BioPlx, Inc. | Methods and compositions to prevent microbial infection |
| US20210393711A1 (en) | 2018-10-11 | 2021-12-23 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Bacteria expressing single chain antibodies against toll-like receptors |
| US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
| US12537071B1 (en) | 2020-07-22 | 2026-01-27 | David Gordon Bermudes | Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins |
| JP7764009B2 (ja) * | 2021-03-26 | 2025-11-05 | 国立研究開発法人農業・食品産業技術総合研究機構 | 環境によって制御される生存能を有する細胞 |
| CN117460416A (zh) * | 2021-04-05 | 2024-01-26 | 马里兰大学派克分院 | 沙门氏菌疫苗 |
| WO2025240926A1 (en) * | 2024-05-17 | 2025-11-20 | University Of Iowa Research Foundation | Neisseria gonorrhoeae vaccines and treatments and methods of use thereof |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4968619A (en) * | 1976-09-27 | 1990-11-06 | Research Corporation | Modified microorganisms and method of preparing and using same |
| US4190495A (en) | 1976-09-27 | 1980-02-26 | Research Corporation | Modified microorganisms and method of preparing and using same |
| US4506013A (en) * | 1980-10-03 | 1985-03-19 | Eli Lilly And Company | Stabilizing and selecting recombinant DNA host cells |
| US4436815A (en) * | 1981-11-27 | 1984-03-13 | Eli Lilly And Company | Method for stabilizing and selecting recombinant DNA containing host cells |
| US4650761A (en) * | 1981-11-27 | 1987-03-17 | Eli Lilly And Company | Method for stabilizing and selecting recombinant DNA containing host cell |
| US5702916A (en) * | 1982-09-16 | 1997-12-30 | Gx Biosystems A/S | Biological Containment |
| US5190931A (en) | 1983-10-20 | 1993-03-02 | The Research Foundation Of State University Of New York | Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA |
| US5855880A (en) * | 1987-06-04 | 1999-01-05 | Washington University | Avirulent microbes and uses therefor |
| US5387744A (en) * | 1987-06-04 | 1995-02-07 | Washington University | Avirulent microbes and uses therefor: Salmonella typhi |
| US5468485A (en) * | 1987-06-04 | 1995-11-21 | Washington University | Avirulent microbes and uses therefor |
| US5294441A (en) * | 1987-06-04 | 1994-03-15 | Washington University | Avirulent microbes and uses therefor: salmonella typhi |
| JPH04501351A (ja) * | 1987-10-07 | 1992-03-12 | ワシントン ユニバーシティ | 細胞の遺伝的集団において所望の組換え遺伝子を維持する方法 |
| US5185431A (en) * | 1988-08-31 | 1993-02-09 | Eisai Co., Ltd. | Recombinant natural killer cell activator |
| DE3936408A1 (de) * | 1989-11-02 | 1991-05-08 | Merck Patent Gmbh | Ueberexpression von proteinen in rekombinanten wirtszellen |
| IE892893A1 (en) * | 1990-03-11 | 1991-09-25 | Charles O Kane | Phage-like bacteriocins |
| AU9094191A (en) * | 1990-11-21 | 1992-06-25 | Washington University | Recombinant avirulent salmonella antifertility vaccines |
| US5599537A (en) * | 1990-12-18 | 1997-02-04 | The General Hospital Corporation | Salmonella virulence genes |
| US5843426A (en) * | 1990-12-18 | 1998-12-01 | The General Hospital Corporation | Salmonella vaccines |
| US5695983A (en) * | 1990-12-18 | 1997-12-09 | The General Hospital Corporation | Salmonella vaccines |
| US5589380A (en) * | 1992-06-05 | 1996-12-31 | University Of Maryland At Baltimore | Isolated DNA molecule encoding SHET1 of Shigella flexneri 2a and mutant Shigella flexneri 2a |
| JPH08506963A (ja) * | 1993-02-22 | 1996-07-30 | ザ ジェネラル ホスピタル コーポレーション | 生ワクチン菌株における異種抗原 |
| AU1257495A (en) * | 1993-11-18 | 1995-06-06 | Chiron Corporation | Compositions and methods for utilizing conditionally lethal genes |
| US5733760A (en) * | 1994-08-05 | 1998-03-31 | Virus Research Institute | Salmonella vectors encoding truncated pag fusion protein, method of making, and uses thereof |
| US5681745A (en) * | 1995-05-01 | 1997-10-28 | Trustees Of Boston University | Biotin-binding containment systems |
| WO1996040947A1 (en) * | 1995-06-07 | 1996-12-19 | Washington University | Recombinant bacterial system with environmentally limited viability |
| AU7301698A (en) * | 1996-11-22 | 1998-06-10 | Human Genome Sciences, Inc. | Thermostable polymerases having altered fidelity |
| US6024961A (en) * | 1997-11-14 | 2000-02-15 | Washington University | Recombinant avirulent immunogenic S typhi having rpos positive phenotype |
| US6780405B1 (en) * | 2000-04-28 | 2004-08-24 | Avant Immunotherapeutics, Inc. | Regulated antigen delivery system (RADS) |
| WO2002096195A1 (en) * | 2001-05-31 | 2002-12-05 | Enteromed, Inc. | Treatment or replacement therapy using transgenic stem cells delivered to the gut |
| US20030082511A1 (en) * | 2001-09-25 | 2003-05-01 | Brown Steven J. | Identification of modulatory molecules using inducible promoters |
-
1996
- 1996-06-07 WO PCT/US1996/009774 patent/WO1996040947A1/en not_active Ceased
- 1996-06-07 AT AT96919292T patent/ATE312934T1/de not_active IP Right Cessation
- 1996-06-07 DE DE69635579T patent/DE69635579D1/de not_active Expired - Lifetime
- 1996-06-07 AU AU61664/96A patent/AU711618B2/en not_active Ceased
- 1996-06-07 CA CA002222761A patent/CA2222761A1/en not_active Abandoned
- 1996-06-07 JP JP9501998A patent/JPH11507532A/ja not_active Ceased
- 1996-06-07 EP EP96919292A patent/EP0832255B1/de not_active Expired - Lifetime
- 1996-12-06 US US08/761,769 patent/US6610529B1/en not_active Expired - Lifetime
-
1998
- 1998-07-22 US US09/120,970 patent/US7871604B1/en not_active Expired - Fee Related
-
2003
- 2003-07-15 US US10/620,777 patent/US20040208897A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU6166496A (en) | 1996-12-30 |
| JPH11507532A (ja) | 1999-07-06 |
| US20040208897A1 (en) | 2004-10-21 |
| EP0832255B1 (de) | 2005-12-14 |
| CA2222761A1 (en) | 1996-12-19 |
| WO1996040947A1 (en) | 1996-12-19 |
| US7871604B1 (en) | 2011-01-18 |
| DE69635579D1 (de) | 2006-01-19 |
| EP0832255A1 (de) | 1998-04-01 |
| US6610529B1 (en) | 2003-08-26 |
| AU711618B2 (en) | 1999-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69635579D1 (de) | Rekombinant bakterielle system mit umweltbeschränkte lebensfähigkeit | |
| Moran et al. | Th2 responses to inactivated influenza virus can be converted to Th1 responses and facilitate recovery from heterosubtypic virus infection | |
| Duc et al. | Bacterial spores as vaccine vehicles | |
| ES2152929T3 (es) | Sistema de seleccion negativa de la deaminasa de citosina para terapias y tecnicas de transferencia de genes. | |
| Vanloubbeeck et al. | The immunology of Leishmania infection and the implications for vaccine development | |
| TR199800607T1 (xx) | Dendritik h�cre uyar�c� fakt�r�. | |
| HUP0300793A2 (hu) | Szabályozott antigénszállító rendszer (RADS) | |
| PE20030239A1 (es) | Vacuna de mycoplasma bovis y metodos para reducir la neumonia en animales | |
| EP1117767A4 (de) | Immunmodulation mittels genetischer modifikation von dendritischen zellen und b-zellen | |
| BR0009663A (pt) | Composições de vacinas antibacterianas | |
| Gong et al. | Rickettsia rickettsii outer membrane protein YbgF induces protective immunity in C3H/HeN mice | |
| Dinter et al. | Differentiation of porcine mycoplasma strains | |
| BR0103887C1 (pt) | Composições imunogênicas contendo microesferas biodegradáveis encapsulando antìgenos, vetores gênicos e adjuvantes | |
| MY129859A (en) | Bacterial strains of the bacterium bacillus thuringiensis and uses therefor | |
| Varinrak et al. | Cross-protection conferred by immunization with an rOmpH-based intranasal fowl cholera vaccine | |
| Confer et al. | Serum antibody responses of cattle vaccinated with partially purified native Pasteurella haemolytica leukotoxin | |
| YU49995A (sh) | Polinukleotidna vakcina za virus herpesa | |
| ATE420960T1 (de) | Impfstoffe auf der basis von invasiven bakterien | |
| AU1853995A (en) | Vaccine compositions | |
| CA2128247A1 (en) | Vaccines based on streptokinase | |
| McNeill et al. | Development of a nonantibiotic dominant marker for positively selecting expression plasmids in multivalent Salmonella vaccines | |
| Pourreau et al. | Modulation of the mitogenic PHA response of carp, Cyprinus carpio L., by extracellular products of Aeromonas salmonicida | |
| Rodriguez‐Monroy et al. | Striking activation of NALT and nasal passages lymphocytes induced by intranasal immunization with Cry1Ac protoxin | |
| Blanco et al. | Mycobacterium bovis mutant in the virulence factors PhoP, ESAT-6 and CFP-10 persisted in mouse organs after a year post-vaccination | |
| Dougan et al. | Live bacterial vaccine for delivering antigens to the mammalian immune system. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |